Heyman Richard A. sold $45K of ORIC

Heyman Richard A. sold 3,500 shares of Oric Pharmaceuticals, Inc. (ORIC) at $12.91 on 2026-10-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Heyman Richard A.
Published Oct 2, 2026, 9:50 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 9:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ORIC
Neutral
high confidence
Mentioned
$ORIC
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ORICNeutralLow
01

Why it matters

The disclosed sale is modest and unlikely to move the stock significantly, but it provides transparency for investors.

02

Market read

A routine insider sale with limited market impact; useful for compliance monitoring.

03

What to watch

Potential tax planning or diversification motives behind the 10b5-1 sale.

Relevance 2/10Novelty 2/10Timing: after-hours filing on Oct 2

Background

Form 4 filings disclose insider transactions and are primary sources for such events.

Company-level read

Ticker impact

$ORICNeutralHigh confidence
Context

Director Richard Heyman sold 3,500 shares for $45,199 via a 10b5-1 plan, reducing his stake to 38,300 shares.

Expected impact

likely slight downward pressure as the market prices in the insider sale

Evidence & confidence

The sale is small relative to market cap and disclosed via a Form 4, indicating a routine transaction with limited impact.

Market effects

None significant for the biotech sector.

No regional effect.

Limited to ORIC shareholders.

Counterpoint

The sale could be a signal of upcoming negative news, warranting a short position.

Key entities

  • Oric Pharmaceuticals, Inc.

    Biotech company listed on NASDAQ under ticker ORIC.

  • Richard A. Heyman

    Director of Oric Pharmaceuticals who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ORICMed

Wedbush reiterates Oric Pharmaceuticals stock rating on trial data

Wedbush reiterated an Outperform rating and $14.00 price target for ORIC Pharmaceuticals (ORIC) after its Q3 2026 earnings update. The stock is near its 52-week low at $7.52. InvestingPro values ORIC at $8.57. The company shared positive trial data for rinzimetostat in prostate cancer, with Phase 3 studies ongoing. BTIG and Stifel also issued Buy ratings with higher price targets.

$ORICMedAI 8/10

ORIC® Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Operational and Rinzimetostat Program Updates

Oric Pharmaceuticals, Inc. (ORIC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ORIC ® Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Operational and Rinzimetostat Program Updates Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone, supported by a clinical trial collabo